Table of Contents
ISRN Obstetrics and Gynecology
Volume 2012 (2012), Article ID 854237, 4 pages
Clinical Study

CD8 T-Cell Responses in Incident and Prevalent Human Papillomavirus Types 16 and 18 Infections

1Department of Pathology, College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 502, Little Rock, AR 72205, USA
2Department of Pediatrics, College of Medicine, University of California, San Francisco, 3333 California Street, San Francisco, CA 94143, USA
3Department of Microbiology and Parasitology, College of Basic Medical Sciences, China Medical University, Shenyang 110001, China

Received 2 November 2011; Accepted 14 December 2011

Academic Editors: Y. S. Song and L. C. Zeferino

Copyright © 2012 Hannah N. Coleman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


CD8 T-cell responses were examined in subjects with incident (new following negative visits) or prevalent (lasting ≥ 4 months) human papillomavirus type 16 (HPV16) or human papillomavirus (HPV18) infection. The groups were chosen from a cohort of women being followed every 4 months with cervical cytology and HPV-DNA testing. Enzyme-linked immunospot (ELISPOT) assay was performed at enrollment (time zero) and one year later. At time zero, 1 (6%) of 17 subjects with incident HPV 16/18 infections had positive ELISPOT results which increased to 6 (35%) at one year. For the subjects with prevalent HPV 16/18 infections, the ELISPOT results were similar at time zero (2 (15%) of 15 subjects positive) and at one year (3 (20%)). While all of the 11 women with prevalent HPV16 infection showed clearance one year later, unexpectedly only 1 (25%) of 4 women with prevalent HPV18 infection demonstrated clearance one year later ( 𝑃 = . 0 0 9 ).